Conclusion In summary , the current meta- analysis demonstrated the promising impact of ALA administration on decreasing inflammatory markers such as CRP , IL-6 and TNF-α among patients with MetS and related disorders
Objective This systematic review and meta- analysis of r and omized controlled trials ( RCTs ) was conducted to determine the effect of alpha-lipoic acid ( ALA ) supplementation on the inflammatory markers among patients with metabolic syndrome ( MetS ) and related disorders .
Effects of α-Lipoic Acid on the Plasma Levels of Asymmetric Dimethylarginine in Diabetic End-Stage Renal Disease Patients on Hemodialysis: A Pilot Study
Background / Aim : Endothelial dysfunction due to reduced nitric oxide ( NO ) availability precedes the development of atherosclerosis . Asymmetric dimethylarginine ( ADMA ) , an endogenous inhibitor of NO synthase , is not only a cause of endothelial dysfunction , but also a predictor of the cardiovascular outcome in end-stage renal disease ( ESRD ) patients on hemodialysis ( HD ) .  α-Lipoic acid ( ALA ) , a strong antioxidant , increases NO-mediated vasodilation in diabetic patients . We investigated whether ALA could decrease the plasma level of ADMA in diabetic ESRD patients on HD . Methods : Fifty patients undergoing HD three times per week were r and omized to a treatment group receiving ALA 600 mg/day for 12 weeks or a control group . We measured the plasma levels of cholesterol , albumin , high-sensitivity C-reactive protein , oxidized low-density lipoprotein , hemoglobin A1c , and ADMA in both groups at baseline and at 12 weeks . Results : In the control group , the levels of total cholesterol , serum albumin , high-sensitivity C-reactive protein , oxidized low-density lipoprotein , hemoglobin A1c , and ADMA did not change . In the treatment group , the plasma levels of ADMA decreased significantly from a median of 1.68 ( range 0.45–3.78 ) µM to a median of 1.31 ( range 0.25–3.19 ) µM ( p = 0.001 ) . Conclusion : Considering that ADMA is an independent risk factor for cardiovascular outcome in ESRD patients  , ALA may have the potential of a beneficial effect in them , in part by decreasing the plasma level of ADMA
Conclusion In summary , the current meta- analysis demonstrated the promising impact of ALA administration on decreasing inflammatory markers such as CRP , IL-6 and TNF-α among patients with MetS and related disorders
Objective This systematic review and meta- analysis of r and omized controlled trials ( RCTs ) was conducted to determine the effect of alpha-lipoic acid ( ALA ) supplementation on the inflammatory markers among patients with metabolic syndrome ( MetS ) and related disorders .